A Study to Evaluate the Effects of Giving IL-2 Alone to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 Who Do Not Wish to Receive Anti-HIV Therapy
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Interleukin-2, Dose-Response Relationship, Drug, CD4 Lymphocyte Count, RNA, Viral
Eligibility Criteria
Inclusion Criteria Patients may be eligible for this study if they: Are HIV-positive. Have had at least one CD4 cell count greater than or equal to 350 cells/mm3 within 30 days of study entry. Are at least 18 years old. Agree to abstinence or use of effective methods of birth control 1 month before and during the study. Exclusion Criteria Patients will not be eligible for this study if they: Have a history of a potentially life-threatening autoimmune or inflammatory disease. Abuse alcohol or drugs, or have any serious psychiatric or medical illnesses that would affect their safety or ability to complete the study. Have a history of an AIDS-defining illness. Have a history of cancer, other than Kaposi's sarcoma. Have ever taken IL-2 or any antiretroviral medications. Are pregnant. Are taking certain medications, including anti-seizure medications.
Sites / Locations
- Kobler Ctr. of Chelsea Westminster Hosp. C604-030 CRS